We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Schering, AstraZeneca Partnership to Focus on Anti-Inflammatory Drugs
Schering, AstraZeneca Partnership to Focus on Anti-Inflammatory Drugs
July 27, 2005
Schering AG has signed a collaboration and licensing agreement with AstraZeneca that will focus on the development of selective glucocorticoid receptor agonists (SEGRAs), a new class of anti-inflammatory agents.